Citi raises target price of AKESO (09926) to HK$112.6, maintains "outperform" rating.

CICC CCB International released a research report stating that it has raised the target price of AKESO (09926) by 18% from 95.3 Hong Kong dollars to 112.6 Hong Kong dollars, maintaining a "outperform" rating. The report pointed out that on April 23, AKESO announced that its Phase III head-to-head trial HARMONi6 evaluating the efficacy of PD-1/VEGF AK112 combination chemotherapy compared to BEIGENEPD-1 Tremelimumab monotherapy combined chemotherapy in 1L sNSCLC has achieved strong positive results and met the primary endpoint of progression-free survival (PFS) earlier than expected by the bank, which is expected to have a positive impact on sales growth. Therefore, the bank has adjusted its forecasts for this event.